Back

Matthew Porteus

Professor, Stanford University

Professor Porteus is a physician-scientist who has focused on developing precision genetic engineering strategies to cure hemoglobinopathies and  rare genetic diseases of the blood and immune system. He is the Director of the Stanford Center for Definitive and Curative Medicine and is the President-Elect of the American Society of Gene and Cell Therapy (ASGCT). In addition to his academic work, he has been involved in the founding of several biotechnology companies including CRISPR Therapeutics and Kamau Therapeutic and is a scientific advisor to several more.

Dear delegates,

In light of the latest developments and as a precautionary measure, the Cyprus Presidency of the Council of the EU 2026 has decided to postpone this week’s Presidency Conference Advancement of Treatments for Rare Diseases, scheduled to take place in Cyprus 5–6 March 2026.

Further information regarding possible re-arrangement and new dates will be communicated in due course.

We apologise for the inconvenience caused by these adjustments and thank you for your understanding.

Yours sincerely,
The Organizing Committee
Conference “Advancement of Treatments for Rare Diseases”
Cyprus Presidency of the Council of the European Union 2026